Lack in Biological Technology

Digital Healthcare Conference, Mithridion, lack of degrees

At the recent Digital Healthcare Conference top healthcare decision makers met to discuss how information technology can improve patient safety, decrease medical costs, and improve the delivery of healthcare. Meanwhile at the Entrepreneurs Conference held in Milwaukee, Mithridion won the Governors ...

While some bemoan lack of venture capital, entrepreneur touts `bootstrapping' for cash

Another in a line of reports paints a bleak picture for entrepreneurs seeking venture capital in Wisconsin, suggesting that such financing could be at its lowest level in 10 years if patterns through the third quarter continue to year's end. The Money Tree Survey , released last week by Pricewa...

Doyle laments lack of progress on stem cell bill

Madison, Wis. - Wisconsin Gov. Jim Doyle , noting that May 24 is the one-year anniversary of House passage of bipartisan legislation to overturn President Bush's ban on federal funding for embryonic stem cell research, said Congressional inaction is delaying critical scientific research. D...

Research explains why women lack equal access to angel capital

Madison, Wis . - New research showing why women entrepreneurs receive less angel funding than their male counterparts comes as no surprise to the managers of a Wisconsin angel capital fund designed for women. The research, conducted by Jeffrey Sohl, director of the Center for Venture Research ...

ALPCO Introduces a Mouse HMW and Total Adiponectin ELISA

...ng HMW adiponectin in mouse samples do not have a corresponding method for assessing total adiponectin available from the same manufacturer. Given the lack of an international reference standard for adiponectin, the determination of both HMW and total adiponectin using the same ELISA is preferable to elim...

GenVec Reports Second Quarter 2009 Financial Results

...f any, of GenVec's proposed product candidates; dependence on the efforts of third parties; dependence on intellectual property; and risks that we may lack the financial resources and access to capital to fund our operations. Further information on the factors and risks that could affect GenVec's busines...

Transposagen Creates a Rat Model of the Human Immune System

...in have created and characterized the world's first rat model of severe combined immunodeficiency, or SCID. The Transposagen rat has a nearly complete lack of the major components of the immune system. Transposagen will be marketing SCID rats to pharmaceutical and biotechnology companies. "Transposagen is...

Cadence Pharmaceuticals Reports Second Quarter 2009 Financial Results

...er of 2009 and 9,240,307 shares of common stock pursuant to an effective shelf registration in the first quarter of 2008, there is a lack of comparability in the per share amounts between the 2009 and 2008 periods presented. CADENCE ...

Poniard Pharmaceuticals Reports Second Quarter 2009 Financial Results and Provides a Corporate Update

...any's ability to preserve and protect intellectual property rights; the Company's dependence on third-party manufacturers and suppliers; the Company's lack of sales and marketing experience; the Company's ability to attract and retain key personnel; changes in technology, government regulation and general...

Nile Therapeutics, Inc. Announces Dosing of First Patient in Phase 2 Study of CD-NP for the Treatment of Acute Heart Failure

... capital to fund its product development programs to completion, Nile's reliance on third-party researchers to develop its product candidates, and its lack of experience in developing and commercializing pharmaceutical products. Additional risks are described in greater detail in the reports Nile files wi...

DOR BioPharma Receives FDA Orphan Drug Designation for orBec(R) for the Treatment of Chronic Gastrointestinal GVHD

... that product development and commercialization efforts will not be reduced or discontinued due to difficulties or delays in clinical trials or due to lack of progress or positive results from research and development efforts, that it will be able to successfully obtain any further grants and awards, main...

Model predicts evolution of Mediterranean landscape following fires

...d 100 years. However, this evolution may be affected by a range of factors. The results show, for example, that if the ground is dry, or there is a lack of Holm oak acorns, a burned area can turn into a pine forest within 30 years. However, in good water and soil conditions, the ecosystem could develop...

Insmed to Host Second Quarter 2009 Conference Call

...tainties include, without limitation, risks that product candidates may fail in the clinic or may not be successfully marketed or manufactured, we may lack financial resources to complete development of product candidates, the FDA may interpret the results of studies differently than us, competing product...

GenVec Expands Contract Supporting Malaria Vaccine Program

...f any, of GenVec's proposed product candidates; dependence on the efforts of third parties; dependence on intellectual property; and risks that we may lack the financial resources and access to capital to fund our operations. Further information on the factors and risks that could affect GenVec's busines...

Histogen Hair Regrowth Clinical Trial Presented at ISHRS Annual Meeting

... suffer from hair loss, it is estimated that only 2-7% seek surgical or pharmacological treatment. The same is true internationally due to the general lack of effective medical options for this widespread condition. "Hair restoration treatments range in effectiveness and invasiveness. All of the ...

SAPHRIS(R) (asenapine) Meets Primary Endpoint in Long-Term Extension Study in Patients With Predominant, Persistent Negative Symptoms of Schizophrenia

...tension study in patients with predominant, persistent negative symptoms of schizophrenia. Negative symptoms of schizophrenia include apathy, lack of emotion and poor social functioning, among others. In the study, these symptoms were assessed using the validated 16-item Negative Symptom Assessm...

Growing Awareness and Increased Investments Lead to Growth of Biotechnology Applications in the Food & Beverage and Dietary Supplements Sector, Reveals Frost & Sullivan

...consumer awareness about these new age functional ingredients and their health benefits is still low: a key challenge for this industry. Additionally, lack of defined regulations regarding usage of such products or guidelines on health claims in India is a growth restraining factor. According to a ...

Northwest Biotherapeutics Announces Plans to De-list From AIM and Consolidate its Stock Market Listing in U.S.

...which the Company has faced conflicting requirements on an ongoing basis; The management time taken up with the Company's AIM listing; The lack of significant liquidity or other current benefits from the Company's AIM listing; and The ability to continue the Company's U.S. listing, unaff...

Sigma-Aldrich (Nasdaq:SIAL) Reports Q2 2009 Diluted EPS of $0.68; YTD Diluted EPS up 1.5% to $1.36. Full Year 2009 Guidance Reaffirmed, With 2009 Diluted EPS Expected to Exceed 2008's $2.65.

...products, particularly from the pharmaceutical and hi-tech industries, is expected to continue to reflect the uncertainty in these markets. Due to the lack of clarity on allocations and timing of stimulus funding by the U.S. government, no benefit of this funding is included in this outlook. Currency is ...

DNA Software, Inc. Awarded $2.5 M in NIH Funding to Develop Pioneering Nucleic Acid-based Technologies

... of interesting macromolecular sequences, but there is a shortage of corresponding 3-dimensional (3D) structural information. As a result, there is a lack of structural understanding of the mechanism of the vast majority of known nucleic acid sequences. Half of all clinically used antibiotics target bac...

Novavax Announces Selection of a Respiratory Syncytial Virus Vaccine Candidate for Advanced Preclinical Studies

...l resources and patient enrollment from drug candidates in development by other companies with greater resources and visibility; and risks that we may lack the financial resources and access to capital to fund our operations including further preclinical work and clinical trials. Further information o...

Junying Yu, Leading Stem Cell Researcher, Joins Cellular Dynamics International

... "I'm excited to join the team of scientists at CDI working towards personalized therapeutics. In vitro drug testing can be severely limited by the lack of physiologically relevant models arising from non-human animal models or models that do not appropriately reflect the target population. iPS cell t...

The MedZilla Report: June 2009 Employment Outlook for Biotech/Pharma/Health

...ough it is questionable just how many administrative employees can be let go from a hospital or hospital system before patient care suffers not from a lack of doctors and nurses but the inability to keep track of what's going on. "Companies continue to downsize even after significant layoffs have alr...

Hygeia Therapeutics Signs an Exclusive License with Yale University for Potent, Safe Topical Anti-Androgens

...unced that it has enhanced its pipeline with the acquisition of a series of potent topical anti-androgens. The lead compound, HYG-440, is expected to lack systemic effects. The addition of the series of anti-androgens covering four different structural classes, adds to the Company portfolio of topically...

Nile Therapeutics, Inc. Completes $3.4 Million Private Placement

... capital to fund its product development programs to completion, Nile's reliance on third-party researchers to develop its product candidates, and its lack of experience in developing and commercializing pharmaceutical products. Additional risks are described in greater detail in the reports Nile files wi...

Studies Presented at International Conference on Alzheimer's Disease Reveal Substantial Economic Costs and Caregiver Burden Associated with Alzheimer's Disease

... Specifically, this poster presented an interim analysis that found caregivers reported experiencing increased disruption in daily schedules, greater lack of family support, and more time devoted to being a caregiver as AD patients' dependence increased. "Given these recent findings, it's vit...

Inspiration Biopharmaceuticals Presents Safety Data on IB1001, a Novel Recombinant Factor IX for the Treatment of Hemophilia at the International Society on Thrombosis and Haemostasis (ISTH) Annual Meeting

...atment is in excess of seven billion dollars annually. There are two types of hemophilia, hemophilia A and hemophilia B. Hemophilia A is caused by a lack of Factor VIII and hemophilia B is caused by a deficiency of Factor IX. About Inspiration Biopharmaceuticals Inspiration Biopharmaceut...

Evidence for a New Genetic Link to Therapeutic Efficacy for Alzheimer's Disease

...ly. The national Family Caregiver Alliance estimates that approximately 80 percent of caregivers provide unpaid assistance seven days a week. With the lack of innovative new medications for AD, both patients and caregivers are seeking alternatives to improve quality of life. About Accera, Inc. ...

Poniard Pharmaceuticals Appoints Gary A. Lyons to Board of Directors

...any's ability to preserve and protect intellectual property rights; the Company's dependence on third-party manufacturers and suppliers; the Company's lack of sales and marketing experience; the Company's ability to attract and retain key personnel; changes in technology, government regulation and general...

Cadila Pharmaceuticals Launches Joint Venture With Novavax in India

...l resources and patient enrollment from drug candidates in development by other companies with greater resources and visibility; and risks that we may lack the financial resources and access to capital to fund our operations including further clinical trials. Further information on the factors and risks t...

Nile Therapeutics, Inc. To Raise $3.4 Million in Private Placement

... capital to fund its product development programs to completion, Nile's reliance on third-party researchers to develop its product candidates, and its lack of experience in developing and commercializing pharmaceutical products. Additional risks are described in greater detail in the reports Nile files wi...

DOR BioPharma Announces Issuance of European Patent for its LPM(TM) Oral Drug Delivery Technology

... that product development and commercialization efforts will not be reduced or discontinued due to difficulties or delays in clinical trials or due to lack of progress or positive results from research and development efforts, that it will be able to successfully obtain any further grants and awards, main...

The Leukemia & Lymphoma Society and The International Waldenstrom's Macroglobulinemia Foundation Partner to Develop Cell Lines to Advance Research

...M cell lines may not accurately represent the disease. "Numerous scientists studying WM report that one of the barriers to finding a cure is the lack of a standardized WM cell line," said LLS Chief Scientific Officer Louis J. DeGennaro, Ph.D. "Together, LLS and IWMF are committed to seeing this crit...

Celtic Pharma Holdings Announces Investment in Novacta Biosystems Limited

...i-infective properties but have historically been underexploited owing to a lack of research tools, a challenge that Novacta has successfully addressed thro...tibiotics, a drug class that, until now, has been underexploited due to the lack of adequate research tools. Novacta's lantibiotic platform has given rise t...

DOR BioPharma Announces Publication of orBec(R) Clinical Pulmonary Data in Bone Marrow Transplantation

... that product development and commercialization efforts will not be reduced or discontinued due to difficulties or delays in clinical trials or due to lack of progress or positive results from research and development efforts, that it will be able to successfully obtain any further grants and awards, main...

Insmed Announces Results of IPLEX(TM) Phase II Trial in Myotonic Muscular Dystrophy

...anufactured, competing products may be more successful, our continuing efforts to grow the business and develop IPLEX(TM) may be unsuccessful , we may lack financial resources to complete development of product candidates, we may be unsuccessful in finding or pursuing business development initiatives, and...

Spherix Announces Termination of Arla License Agreement

...tainties include, without limitation, risks that product candidates may fail in the clinic or may not be successfully marketed or manufactured, we may lack financial resources to complete development of Naturlose, the FDA may interpret the results of studies differently than us, competing products may be ...

Spherix Announces Full-Scale Production of Pharmaceutical Tagatose

...tainties include, without limitation, risks that product candidates may fail in the clinic or may not be successfully marketed or manufactured, we may lack financial resources to complete development of Naturlose, the FDA may interpret the results of studies differently than us, competing products may be ...

Government Mandates Create Guaranteed Market for Bio-Fuel, Says Frost & Sullivan

...ng bio-diesel and its benefits. In many cases, oil companies remain hesitant about offering bio-diesel blends. Also, unimaginable feedstock prices and lack of government initiatives in some countries, in terms of establishing favorable tax incentives for bio-diesel supply and uptake, is restraining market...

Novavax CEO to Present at Phacilitate Vaccine Forum Barcelona 2009

...l resources and patient enrollment from drug candidates in development by other companies with greater resources and visibility; and risks that we may lack the financial resources and access to capital to fund our operations including further clinical trials. Further information on the factors and risks t...